Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30742% above fair value
$50.24−0.86 (-1.68%)
Close on Nov 18, 2026Market cap $4.74BP/E –Yield –
Travere Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Travere Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $591.33M, up 77.1% year over year. For fiscal 2026 it was $490.73M, up 110.5% from the year before. Over ten years it grew 17.3% a year on average. The highest annual figure on record is $490.73M in fiscal 2026.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Dec 31, 2025 | $490.73M | +110.5% |
| FY2025 | Dec 31, 2024 | $233.18M | +60.5% |
| FY2024 | Dec 31, 2023 | $145.24M | +32.7% |
| FY2023 | Dec 31, 2022 | $109.46M | -17.0% |
| FY2022 | Dec 31, 2021 | $131.84M | -33.5% |
| FY2021 | Dec 31, 2020 | $198.32M | +13.1% |
| FY2020 | Dec 31, 2019 | $175.34M | +6.8% |
| FY2019 | Dec 31, 2018 | $164.25M | +6.0% |
| FY2018 | Dec 31, 2017 | $154.94M | +16.0% |
| FY2017 | Dec 31, 2016 | $133.59M | +33.7% |
| FY2016 | Dec 31, 2015 | $99.89M | +254.2% |
| FY2015 | Dec 31, 2014 | $28.20M | – |
| FY2014 | Dec 31, 2013 | $0 | – |
| FY2012 | Feb 29, 2012 | $0 | – |
| FY2011 | Feb 28, 2011 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027 | Jun 30, 2026 | $169.58M | +48.2% |
| Q1 FY2027 | Mar 31, 2026 | $127.20M | +55.6% |
| Q4 FY2026 | Dec 31, 2025 | $129.69M | +73.4% |
| Q3 FY2026 | Sep 30, 2025 | $164.86M | +162.1% |
| Q2 FY2026 | Jun 30, 2025 | $114.45M | +111.5% |
| Q1 FY2026 | Mar 31, 2025 | $81.73M | +97.5% |
| Q4 FY2025 | Dec 31, 2024 | $74.79M | +66.0% |
| Q3 FY2025 | Sep 30, 2024 | $62.90M | +69.6% |
| Q2 FY2025 | Jun 30, 2024 | $54.12M | +68.1% |
| Q1 FY2025 | Mar 31, 2024 | $41.37M | +33.9% |
| Q4 FY2024 | Dec 31, 2023 | $45.06M | +53.6% |
| Q3 FY2024 | Sep 30, 2023 | $37.10M | +32.1% |
| Q2 FY2024 | Jun 30, 2023 | $32.20M | +12.4% |
| Q1 FY2024 | Mar 31, 2023 | $30.89M | +31.9% |
| Q4 FY2023 | Dec 31, 2022 | $29.34M | -48.8% |
| Q3 FY2023 | Sep 30, 2022 | $28.08M | -58.8% |
| Q2 FY2023 | Jun 30, 2022 | $28.63M | -47.6% |
| Q1 FY2023 | Mar 31, 2022 | $23.41M | -50.6% |
| Q4 FY2022 | Dec 31, 2021 | $57.25M | +12.3% |
| Q3 FY2022 | Sep 30, 2021 | $68.22M | +33.4% |
| Q2 FY2022 | Jun 30, 2021 | $54.62M | +12.8% |
| Q1 FY2022 | Mar 31, 2021 | $47.41M | -0.8% |
| Q4 FY2021 | Dec 31, 2020 | $50.98M | +9.2% |
| Q3 FY2021 | Sep 30, 2020 | $51.14M | +15.2% |
| Q2 FY2021 | Jun 30, 2020 | $48.43M | +8.3% |
| Q1 FY2021 | Mar 31, 2020 | $47.77M | +20.7% |
| Q4 FY2020 | Dec 31, 2019 | $46.69M | +6.7% |
| Q3 FY2020 | Sep 30, 2019 | $44.37M | +9.0% |
| Q2 FY2020 | Jun 30, 2019 | $44.71M | +8.2% |
| Q1 FY2020 | Mar 31, 2019 | $39.57M | +3.0% |
| Q4 FY2019 | Dec 31, 2018 | $43.77M | +3.8% |
| Q3 FY2019 | Sep 30, 2018 | $40.71M | +0.9% |
| Q2 FY2019 | Jun 30, 2018 | $41.34M | +6.5% |
| Q1 FY2019 | Mar 31, 2018 | $38.43M | +14.3% |
| Q4 FY2018 | Dec 31, 2017 | $42.18M | +13.0% |
| Q3 FY2018 | Sep 30, 2017 | $40.34M | +18.8% |
| Q2 FY2018 | Jun 30, 2017 | $38.80M | – |
| Q1 FY2018 | Mar 31, 2017 | $33.62M | – |
| Q4 FY2017 | Dec 31, 2016 | $37.33M | – |
| Q3 FY2017 | Sep 30, 2016 | $33.95M | – |
See a number that looks wrong?